Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.
Journal: British journal of haematology
Published: February 25, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.
Journal: American journal of hematology
Published: November 10, 2025
Bispecific antibody therapy for lymphoma.
Journal: Best practice & research. Clinical haematology
Published: October 14, 2024
A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.
Journal: Leukemia & lymphoma
Published: September 20, 2024
ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells.
Journal: British journal of haematology
Published: July 23, 2024
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Journal: The Lancet. Oncology
Published: July 15, 2024
Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy.
Journal: The oncologist
Published: March 07, 2024
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia.
Journal: NEJM evidence
Published: February 06, 2024
Last Updated: 09/26/2026